Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Phase 4
Completed
- Conditions
- Dry Eye SyndromesKeratoconjunctivitis Sicca
- Interventions
- Drug: sodium hyaluronate 0.18% (VISMED® Multi)
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2011-09-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 82
- Registration Number
- NCT00987727
Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT00986401
Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
Not Applicable
Completed
- Conditions
- Mid-facial Volume Deficit Related to Aging
- Interventions
- Device: Juvéderm® VOLUMA XC
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 345
- Registration Number
- NCT00978042
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
Phase 2
Completed
- Conditions
- Rhegmatogenous Macula-off Retinal Detachment
- Interventions
- Drug: 400 ug Brimonidine ImplantDrug: 200 ug Brimonidine ImplantOther: Sham (no implant)
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT00972374
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
Phase 4
Completed
- Conditions
- Hypotrichosis
- Interventions
- Drug: vehicle sterile solution (placebo)
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 89
- Registration Number
- NCT00958035
Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms
Phase 4
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 71
- Registration Number
- NCT00938704
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
Not Applicable
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 47
- Registration Number
- NCT00932477
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Phase 4
Completed
- Conditions
- ObesityOveractive BladderIncontinence
- Interventions
- Other: placebo
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 127
- Registration Number
- NCT00932022
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Phase 3
Completed
- Conditions
- Urinary IncontinenceOveractive Bladder
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 829
- Registration Number
- NCT00915525
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: onabotulinumtoxinADrug: normal saline
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 557
- Registration Number
- NCT00910845
© Copyright 2025. All Rights Reserved by MedPath